Physician profile
Kerri Langer
NPI 1184943920
$4,447.59
in general payments reported to CMS, 2019-2025
23 companies · $881 in 2025
The $881 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,202 · 2020: $274 · 2021: $218 · 2022: $428 · 2023: $809 · 2024: $636 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,254 · Education: $71.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,254.47 |
| Education | $71.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $726.09 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $498.65 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $472.45 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $390.92 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $332.34 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $307.34 | 2021-2025 | Aristada, Lybalvi |
| Allergan, INC. | $296.21 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $262.18 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $238.97 | 2022-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $202.43 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $124.34 | 2019-2025 | Fanapt |
| Bausch Health US, LLC | $103.86 | 2019-2024 | Aplenzin |
| Avanir Pharmaceuticals, INC. | $98.70 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $69.01 | 2023-2024 | Quviviq |
| Adlon Therapeutics L.P. | $54.98 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $53.66 | 2023-2025 | Azstarys |
| Neos Therapeutics, LP | $53.21 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $46.13 | 2019-2024 | Spravato |
| Shire North American Group INC | $41.94 | 2019 | |
| Merck Sharp & Dohme LLC | $23.88 | 2023 | Belsomra |
| Neuronetics, INC. | $19.55 | 2020 | |
| Alfasigma USA, INC. | $19.52 | 2020 | |
| Eisai INC. | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerri Langer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.